STOCK TITAN

ALLURION TECHNOLOGIES INC - ALUR STOCK NEWS

Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.

Allurion Technologies Inc (ALUR) delivers innovative weight management solutions through its swallowable gastric balloon and integrated digital platform. This page provides authorized updates on corporate developments, clinical advancements, and strategic initiatives shaping the future of non-invasive obesity treatment.

Investors and healthcare professionals will find timely announcements including quarterly earnings reports, FDA regulatory updates, partnerships with medical institutions, and new clinical study findings. Our curated news collection ensures transparent access to material events affecting the company's position in the medical device sector.

Key content categories include product innovation timelines, peer-reviewed research publications, executive leadership changes, and global expansion updates. Each announcement is sourced directly from official corporate communications to maintain accuracy and compliance with financial disclosure standards.

Bookmark this page for streamlined access to Allurion's latest developments in AI-powered patient monitoring systems and procedure-less weight loss technologies. Regularly updated to reflect the company's progress in merging medical devices with digital health solutions.

Rhea-AI Summary

Allurion Technologies (NYSE: ALUR) announced its Q1 2024 financial results with a revenue of $9.4 million, a 14% increase from Q4 2023 but a decrease from $14.1 million in Q1 2023. Procedural volume rose 12% year-over-year and 22% sequentially. Cash burn decreased to $8.4 million from $22 million in Q4 2023. Notable developments include treating the first NHS patient with the Allurion Balloon, launching the VCS digital platform in the U.S., and securing $48 million in financing. Operating expenses were reduced significantly, but a year-over-year revenue decline and lower gross profit margins were noted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.76%
Tags
-
Rhea-AI Summary

Allurion Technologies, Inc. (NYSE: ALUR) announced three scientific presentations at IFSO-European Chapter 2024, highlighting 80% sustained weight loss at three years with the Allurion Program and successful outcomes of an AI-powered conversational agent for obesity treatment. The data showcased positive long-term weight maintenance results and patients' healthier eating habits post-program. Additionally, the innovative AI-powered weight loss coach, Coach Iris, received positive feedback for its personalized, trustworthy, and empathetic approach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
none
-
Rhea-AI Summary

Allurion Technologies, Inc. announced preliminary first quarter 2024 results, with quarter-over-quarter revenue growth, procedural volume growth, and a significant decrease in cash burn. The company expects revenue between $9.2 million to $9.3 million, 12%-13% higher than the fourth quarter of 2023, procedural volume growth of 22%, and reduced cash burn of $8 million to $9 million. Allurion remains optimistic about future growth and business opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) closes a $48 million convertible senior secured note financing with RTW Investments, reducing interest expenses, extending cash runway, and strengthening the partnership. The transaction simplifies the capital structure, lowers the interest rate to 6%, and extends the maturity of the debt. The funding will be used to repay existing term loans, providing operational flexibility and enhancing future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
none
-
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) announces the commercial availability of its Virtual Care Suite (VCS) in the United States, a comprehensive weight-loss management suite powered by AI. The VCS aims to enhance patient outcomes and satisfaction through remote patient monitoring, telehealth, and care team collaboration. The addition of Coach Iris, a 24/7 AI-powered weight loss coach, further personalizes the behavior change program. The VCS has shown to improve patient results, engagement, and satisfaction, with clinics experiencing an additional 11% weight loss and a 17% increase in Net Promoter Score (NPS). Allurion will showcase the VCS at the Obesity Medicine Conference in Denver on April 25, introducing a new version of Allurion Insights, the web-based dashboard for providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
78.03%
Tags
none
-
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) reported Q4 revenue of $8.2 million and full-year 2023 revenue of $53.5 million, reiterating 2024 guidance. The company completed enrollment in the AUDACITY pivotal trial ahead of schedule, conducted research on healthcare professionals and patients, and treated the first UK NHS-reimbursed patients with the Allurion Balloon. Despite macroeconomic challenges, Allurion saw a 30% increase in procedural volume. The company expects 2024 revenue of $60-65 million, gross margins of 77-79%, and a cash burn of $30 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) will be participating in the 34th Annual Oppenheimer Healthcare MedTech & Services Conference on March 12 - 13, 2024. The company's CEO and CFO will present at the event, with a live webcast available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.04%
Tags
conferences
-
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) will report Q4 2023 financial results on March 21, 2024. A conference call will follow to discuss results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.31%
Tags
conferences earnings
-
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) to participate in the 44th Annual Cowen Health Care Conference. CEO and CFO to present on March 5, 2024, at 9:50 a.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) will be participating in the BTIG Snowbird Conference from February 12-14, 2024. CEO Shantanu Gaur and CFO Chris Geberth will be available for investor 1x1 meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences
ALLURION TECHNOLOGIES INC

NYSE:ALUR

ALUR Rankings

ALUR Stock Data

13.95M
5.09M
13.85%
22.25%
2.11%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
NATICK